ArticleVaccine: X2023

Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan.

Takuhiro Sonoyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.